Patents by Inventor Roland C. Maude-Griffin
Roland C. Maude-Griffin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10743779Abstract: A system and method for controlling a monitoring mode or treatment mode of an implantable medical device based on the detection of an external signal. The system and related method allow for more frequent monitoring of medical parameters at times where more frequent monitoring is necessary, such as during or after a dialysis session, with less frequent monitoring at other times, allowing for a more efficient medical device. The invention also allows for the frequency or mode of treatment by the implantable medical device, or the transmission of data from the implantable medical device to be controlled based on the external signal.Type: GrantFiled: February 2, 2016Date of Patent: August 18, 2020Assignee: Medtronic, Inc.Inventors: John Burnes, Rebecca Poindexter, Daniel Bloomberg, Christopher M. Hobot, Roland C. Maude-Griffin
-
Publication number: 20180263511Abstract: A system and method for controlling a monitoring mode or treatment mode of an implantable medical device based on the detection of an external signal. The system and related method allow for more frequent monitoring of medical parameters at times where more frequent monitoring is necessary, such as during or after a dialysis session, with less frequent monitoring at other times, allowing for a more efficient medical device. The invention also allows for the frequency or mode of treatment by the implantable medical device, or the transmission of data from the implantable medical device to be controlled based on the external signal.Type: ApplicationFiled: February 2, 2016Publication date: September 20, 2018Applicant: Medtronic, Inc.Inventors: John Burnes, Rebecca Poindexter, Daniel Bloomberg, Christopher M. Hobot, Roland C. Maude-Griffin
-
Patent number: 9937344Abstract: In some examples, the disclosure relates to a systems, devices, and techniques for delivering electrical stimulation therapy to a patient. In one example, the disclosure relates to a method including delivering a series of pulses with alternating pulse polarities to a gastrointestinal tract of a patient. The series of pulses includes at least a first pulse of a first polarity, a second pulse of a second polarity, and a third pulse of the first polarity, where the first, second and third pulses are delivered in direct succession and in that order. The first and second pulses are separated by a first time delay and the second and third pulses are separated by a second time delay. In some examples, each of the first and second time delays depend on the frequency that the series of pulses are delivered.Type: GrantFiled: September 21, 2010Date of Patent: April 10, 2018Assignee: Medtronic, Inc.Inventors: Warren L. Starkebaum, Roland C. Maude-Griffin, Elizabeth D. Firestone, Carl A. Schu, Orhan Soykan
-
Patent number: 9446234Abstract: The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.Type: GrantFiled: September 24, 2008Date of Patent: September 20, 2016Assignee: Medtronic, Inc.Inventors: Warren L. Starkebaum, Charlene X. Yuan, Roland C. Maude-Griffin, Luiz Geraldo Pivotto
-
Publication number: 20140012348Abstract: The disclosure is directed to techniques for delivering electrical stimulation therapy to support obesity management. The electrical stimulation therapy is configured to cause at least partial gastric distention. Gastric distention tends to induce a sensation of fullness and thereby discourages excessive food intake by the patient. The electrical stimulation therapy may be delivered to the gastrointestinal tract of the patient by electrodes deployed by one or more implantable leads coupled to an electrical stimulator. The electrical stimulator delivers stimulation pulses having a pulse width in a range found to be effective in causing gastric distention.Type: ApplicationFiled: September 13, 2013Publication date: January 9, 2014Applicant: Medtronic, Inc.Inventors: Warren L. Starkebaum, Jiande Chen, Elizabeth D. Firestone, Roland C. Maude-Griffin
-
Patent number: 8538532Abstract: In some examples, electrical stimulation therapy is delivered to support obesity management. The electrical stimulation therapy is configured to cause at least partial gastric distention. Gastric distention tends to induce a sensation of fullness and thereby discourages excessive food intake by the patient. The electrical stimulation therapy may be delivered to the gastrointestinal tract of the patient by electrodes deployed by one or more implantable leads coupled to an electrical stimulator. The electrical stimulator delivers stimulation pulses having a pulse width in a range found to be effective in causing gastric distention.Type: GrantFiled: March 2, 2010Date of Patent: September 17, 2013Assignee: Medtronic, Inc.Inventors: Warren L. Starkebaum, Jiande Chen, Elizabeth D. Firestone, Roland C. Maude-Griffin
-
Publication number: 20120259389Abstract: In some examples, the disclosure relates to a systems, devices, and techniques for delivering electrical stimulation therapy to a patient. In some example, the disclosure relates to systems and methods of treating hyperglycemia in a patient including delivering gastric electrical stimulation (GES) to the patient. Devices, systems and methods according to the disclosure may comprise an implantable stimulator, a blood glucose monitor and/or a food intake sensor. In some examples, a blood glucose level and/or food intake of a patient is detected and GES is delivered to the patient in response to the detection.Type: ApplicationFiled: April 12, 2012Publication date: October 11, 2012Inventors: Warren Starkebaum, John E. Burnes, Roland C. Maude-Griffin
-
Patent number: 7983755Abstract: The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.Type: GrantFiled: September 24, 2008Date of Patent: July 19, 2011Assignee: Medtronic, Inc.Inventors: Warren L. Starkebaum, Charlene X. Yuan, Roland C. Maude-Griffin, Luiz Geraldo Pivotto
-
Patent number: 7957807Abstract: The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.Type: GrantFiled: September 24, 2008Date of Patent: June 7, 2011Assignee: Medtronic, Inc.Inventors: Warren L. Starkebaum, Charlene X. Yuan, Roland C. Maude-Griffin, Luiz Geraldo Pivotto
-
Publication number: 20110071589Abstract: In some examples, the disclosure relates to a systems, devices, and techniques for delivering electrical stimulation therapy to a patient. In one example, the disclosure relates to a method including delivering a series of pulses with alternating pulse polarities to a gastrointestinal tract of a patient. The series of pulses includes at least a first pulse of a first polarity, a second pulse of a second polarity, and a third pulse of the first polarity, where the first, second and third pulses are delivered in direct succession and in that order. The first and second pulses are separated by a first time delay and the second and third pulses are separated by a second time delay. In some examples, each of the first and second time delays depend on the frequency that the series of pulses are delivered.Type: ApplicationFiled: September 21, 2010Publication date: March 24, 2011Applicant: Medtronic, Inc.Inventors: Warren L. Starkebaum, Roland C. Maude-Griffin, Elizabeth D. Firestone, Carl A. Schu, Orhan Soykan
-
Publication number: 20100228313Abstract: The disclosure is directed to techniques for delivering electrical stimulation therapy to support obesity management. The electrical stimulation therapy is configured to cause at least partial gastric distention. Gastric distention tends to induce a sensation of fullness and thereby discourages excessive food intake by the patient. The electrical stimulation therapy may be delivered to the gastrointestinal tract of the patient by electrodes deployed by one or more implantable leads coupled to an electrical stimulator. The electrical stimulator delivers stimulation pulses having a pulse width in a range found to be effective in causing gastric distention.Type: ApplicationFiled: March 2, 2010Publication date: September 9, 2010Applicant: Medtronic, Inc.Inventors: Warren L. Starkebaum, Jiande Chen, Elizabeth D. Firestone, Roland C. Maude-Griffin
-
Publication number: 20090088818Abstract: The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.Type: ApplicationFiled: September 24, 2008Publication date: April 2, 2009Inventors: Warren L. Starkebaum, Charlene X. Yuan, Roland C. Maude-Griffin, Luiz Geraldo Pivotto
-
Publication number: 20090088817Abstract: The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.Type: ApplicationFiled: September 24, 2008Publication date: April 2, 2009Applicant: Medtronic, Inc.Inventors: Warren L. Starkebaum, Charlene X. Yuan, Roland C. Maude-Griffin, Luiz Geraldo Pivotto
-
Publication number: 20090088819Abstract: The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy.Type: ApplicationFiled: September 24, 2008Publication date: April 2, 2009Applicant: Medtronic, Inc.Inventors: Warren L. Starkebaum, Charlene X. Yuan, Roland C. Maude-Griffin, Luiz Geraldo Pivotto